Previous 10 | Next 10 |
Summary I have been watching MSOS since before it launched. Before its collapse, I warned investors about its high concentration in just the five largest MSOs. The ETF has been adding shares extensively, but recently there have been redemptions. I wrote about popular Advis...
Summary New years are a time for reflection, especially those that follow tough years filled with challenging lessons. Hopium and corruption (or its close relative, greed) are thriving in these volatile days. With markets down, inflation high, and war never-ending, investing, and li...
After a ghastly year that's seen the AdvisorShares Pure U.S. Cannabis ETF (NYSEMKT: MSOS) fall by more than 74%, marijuana investors are desperate for a return to the heyday of 2021 when shares were skyrocketing. Alas, there is no relief in sight, and 2023 is likely to be almost as gloomy...
Summary Negative conditions are crashing down all around investors. Make sure companies in your portfolio will survive. Ted Waller shares why some stocks are falling off a cliff. Not all ETFs are created equal - stay away from the leveraged ETFs ('dynamite ready to be lit'). Pin...
Summary I have followed Green Thumb Industries Inc. closely since it went public in 2018. Green Thumb Industries is run well and has executed well thus far. Green Thumb Industries stock is cheap, but it doesn't stand out compared to most peers in my view. Green Thumb Indus...
Summary What have we learned as cannabis investors in 2022? What should we be focused on in 2023? Hope isn't a strategy or a 4 letter word. One of the more attainable goals that I’m setting for myself in 2023 is to write a weekly article focused on what I learned th...
Summary A convergence of factors caused the poor performance of cannabis stocks in 2022. The investing environment has changed, and cannabis investors must change along with it. The potential for investor profits is as strong as ever, but investors must be strategically selective. ...
Summary SAFE Banking once again did not pass. Pharma spends $390 million on lobbying, cannabis just $4 million. While my prediction was wrong, cutting risk kept us ahead of benchmarks. Once again the cannabis industry will not be getting SAFE Banking. Initially, there was opti...
Summary IIPR has pulled back nearly 20% from its recent highs as the Fed's hawkish stance has been a significant drag on the market. Despite that, we assessed the recent pullback is healthy and has improved the reward/risk for investors who missed its October lows. The cannabis indu...
Summary James Baker and Julian Lin are two standout analysts who have joined me over the years for 3 MasterClasses in cannabis investing. This is a compilation of highlights from those shows. As the last episode of the year, and as we've been met with more political gridlock and dis...
News, Short Squeeze, Breakout and More Instantly...
AdvisorShares Trust Pure US Cannabis Company Name:
MSOS Stock Symbol:
NYSE Market:
2024-05-12 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...